Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of ...

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...

The Phase III study was held in Chinese locations and the HER2-targeting ADC Aidixi is unlikely to launch in markets outside ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) ...

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6 mg/kg dose into the phase 3 part of the trial. The ORR ...

The one chip startup building accelerators for something other than AI boasts performance up 10x that of modern GPUs using a ...

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...